Recent machine-extracted executive movements from SEC 8-K Item 5.02 filings, source-linked. Every card cites the SEC source.
Showing 4601–4650 of 18639
each of Diana M. Charletta, principal executive officer of Equitrans, Kirk R. Oliver, principal financial officer of Equitrans, Brian P. Pietrandrea, principal accounting officer of Equitrans, and each other named executive officer of Equitrans ceased his or her respective service as an officer of Equitrans.
On July 19, 2024, Robert T. O’Shaughnessy, the Executive Vice President and Chief Financial Officer of PulteGroup, Inc. (the “Company”), notified the Company that he intends to retire from the Company at the end of 2025.
James L. Ossowski has been promoted to Executive Vice President and Chief Financial Officer of the Company, effective upon Mr. O’Shaughnessy’s retirement from the role of Chief Financial Officer on the Transition Date.
appointed Mr. Steven D. Menneto as the Company's Chief Executive Officer, effective August 5, 2024
On July 21, 2024 the Board of Directors of Arvana Inc, elected Mr. James Kim as Chief Executive Officer of Arvana Inc., effective immediately.
On July 21, 2024, the Board of Directors of Arvana Inc., terminated Mr. Ruairidh Campbell as Chief Executive Officer effective immediately.
On July 15, 2024, the Board of Directors (the “Board”) of Bausch Health Companies Inc. (the “Company”) appointed Jean-Jacques Charhon as the Company’s Executive Vice President and Chief Financial Officer, effective as of August 19, 2024.
On July 19, 2024, Peter S. Ho, Chairman, President and CEO of Bank of Hawaii Corporation (the “Company”) relinquished the title of President of the Company
Anurag Maheshwari, Executive Vice President and Chief Financial Officer, has provided Otis Worldwide Corporation (the “Company”) with notice that he will be resigning his position with the Company, effective August 23, 2024, to pursue external opportunities.
The Board of Directors has appointed Cristina Méndez as the Company’s Executive Vice President and Chief Financial Officer, effective August 23, 2024.
In addition, on July 17, 2024, the board of directors of the Company appointed Alessandro R. Masolo, as Chief Financial Officer, to fill the vacancy created by Mr. Hegazy’s resignation, effective immediately.
On July 16, 2024, Amir Hegazy tendered his resignation as the Chief Financial Officer of Berenson Acquisition Corp. I (the “Company”), effective immediately.
who will step down from such position as of November 30, 2024 and retire on March 1, 2025.
Angie Park has been appointed as the Company’s Chief Financial Officer, effective December 1, 2024, succeeding KC McClure
On July 18, 2024, the sole officer and director of the Company, Zonghan Wu, tendered his resignations as Director, President, Chief Executive Officer, Secretary, and Treasurer of the Company, and appointed Yunyuan Chen as new President, Chief Executive Officer, Secretary, Treasurer, and Director of the Company, effective July 18, 2024.
On July 18, 2024, the sole officer and director of the Company, Zonghan Wu, tendered his resignations as Director, President, Chief Executive Officer, Secretary, and Treasurer of the Company, and appointed Yunyuan Chen as new President, Chief Executive Officer, Secretary, Treasurer, and Director of the Company, effective July 18, 2024.
the Board approved the appointment of Peter Ludlum as the Interim Chief Executive Officer (the “Interim CEO”), effective as of July 20, 2024
Effective as of the Separation Date, Mr. Raad’s employment with the Company shall cease and Mr. Raad shall relinquish all positions, offices, and authority with the Company and any affiliates, including as a member of the Board
On July 16, 2024, in connection with the previously-disclosed resignation of Bo Kruse, the former Executive Vice President, Chief Financial Officer, Treasurer and Secretary of Y-mAbs Therapeutics, Inc.
On July 15, 2024, the Company formally appointed Mr. Essaid (age 57) the Chief Financial Officer of the Company, and Mr. Essaid began his employment as Chief Financial Officer with the Company.
Effective as of July 19, 2024, Tom Alderman, the Company's Chief Financial Officer, is no longer employed by the Company
the Board of Directors of the Company appointed Patricia Huerta, the Company’s Chief Accounting Officer, to serve as the Company's Interim Chief Financial Officer
On July 18, 2024, the Company announced that Matthew Tenorio has been appointed to serve as interim Chief Financial Officer (“Interim CFO”) of the Company, effective July 18, 2024, while the Company conducts a search for its next Chief Financial Officer.
On July 12, 2024, Anuj Aggarwal, Chief Financial Officer of Everspin Technologies, Inc. (the “Company”), notified the Company of his decision to resign effective July 26, 2024 to pursue another opportunity.
appointed Mr. Craig Cunningham as the Chief Financial Officer of the Company, effective as of July 20, 2024.
On July 18, 2024, the Federal Home Loan Bank of Topeka (FHLBank) issued a news release announcing the appointment of Philip Bacchus, age 43, as Chief Financial Officer, effective August 26, 2024.
On July 8, 2024, the Board of Directors elected Gregory C. Anderson to serve as the Company’s chief executive officer effective as of September 1, 2024.
Maurice (Maury) Gallagher, Jr. will retire as the Company’s chief executive officer as of that date but will continue to serve the Company as Executive Chairman.
On July 15, 2024, Steven Rudofsky notified Idaho Copper Corporation (the “Company”) of his resignation from his position as Chief Executive Officer and President of the Company, effective immediately.
Effective July 15, 2024, Andrew Brodkey, the Company’s Chief Operating Officer and Secretary was appointed as Chief Executive Officer and President of the Company, by unanimous written consent of the members of the Board
On July 12, 2024, Intellicheck, Inc., a Delaware corporation (the “Company”), and Jeffrey Ishmael, the Company’s Chief Financial Officer and Chief Operating Officer, entered into a separation agreement (the “Agreement”), pursuant to which Mr. Ishmael’s last date of employment with the Company will be August 31, 2024 (the “Separation Date”).
On July 18, 2024, BeiGene, Ltd. (the “Company”) announced the appointment of Aaron Rosenberg as the Chief Financial Officer (“CFO”) and the principal financial officer of the Company, effective as of July 22, 2024 (the “Effective Date”).
On July 17, 2024, Julia Wang, the Company’s current CFO, resigned as CFO effective July 19, 2024.
On July 5, 2024, the Board accepted the resignation of Mr. Reali, and on the same day appointed Mr. Ciavarella as the Interim Chief Financial Officer to assume the responsibilities as the Company’s principal accounting officer until a suitable replacement is found.
On July 5, 2024, the Board accepted the resignation of Mr. Reali
Christian Rothe has been named Senior Vice President and Chief Financial Officer of the Company, effective August 19, 2024.
Mr. Rothe succeeds Nicholas Gangestad, who has served as Senior Vice President and Chief Financial Officer of the Company since March 2021.
Effective as of July 12, 2024, Eric Wintemute concluded his role as Chief Executive Officer of American Vanguard Corporation (the “Company”).
Mr. Donnelly has also been designated as, and assumed the duties of, the Company’s Acting Chief Executive Officer and acting principal executive officer as of July 12, 2024.
In connection with Mr. Caudill’s appointment as interim Chief Executive Officer, on July 16, 2024, the Company entered into a consulting agreement (the “Consulting Agreement”) with Mr. Caudill.
As previously disclosed in the Initial Form 8-K, in connection with his resignation as President and Chief Executive Officer of the Company, Mr. Fehrman will forfeit all of his unvested restricted stock units and cash incentive awards and repay the $2.0 million signing bonus paid to him upon commencement of his employment with the Company.
appointed Joel D. Anderson to succeed R. Michael Mohan, interim Chief Executive Officer, as the Chief Executive Officer of the Company
appointed Joel D. Anderson to succeed R. Michael Mohan, interim Chief Executive Officer, as the Chief Executive Officer of the Company (the “CEO Succession”), effective as of July 29, 2024
On July 15, 2024, the Board of Directors of Emmaus Life Sciences, Inc. (“we,” “us,” “our,” “Emmaus” or the “company”) appointed Willis Lee as our Chief Executive Officer and eliminated the former offices of interim Co-President.
On July 15, 2024, Remi Barbier, President and Chief Executive Officer of Cassava Sciences, Inc. (the “ Company ” or “ Cassava ”) resigned from the Company, effective as of September 13, 2024
by mutual agreement, James Stanker resigned as Chief Financial Officer of the Company, effective July 15, 2024.
announced the appointment of Mr. Russell Skibsted, Effective July 16, 2024 as its Chief Financial Officer.
Effective on July 15, 2024, Mr. Nelson Cabatuan resigned from his position as the Company’s Chief Financial Officer in order to focus his attention on corporate finance and strategic industry relationships for Lexaria as its Chief Strategic Financial Advisor.
on July 11, 2024, Tracey T. Travis, Executive Vice President and Chief Financial Officer of The Estée Lauder Companies Inc. (the “Company”), notified the Company of her decision to retire effective June 30, 2025.
On July 11, 2024, Paul M. Pickett notified Old Point Financial Corporation (the “Company”) of his decision to resign as Chief Financial Officer & Senior Vice President/Finance and principal financial and accounting officer of the Company and as Chief Financial Officer & Executive Vice President of The Old Point National Bank of Phoebus (the “Bank”), the Company’s wholly owned national bank subsidiary.
Recent executive movements from 8-K Item 5.02 filings, source-linked. Cards are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.